Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Radha Bernander

Physician Assistant, Medical Katy, TX Physician Assistant

NPI 1396273595 CMS profile 10681322

21308 Provincial Blvd, Katy, TX 77450

Open in the dashboard

General payments

$73,636

874 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Radha Bernander of Katy, TX is reported in the CMS Open Payments database as having received $73,636 across 874 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $33,447 198
2024 General $30,621 210
2023 General $3,877 186
2022 General $2,935 130
2021 General $2,756 150

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Radha Bernander
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Radha Bernander were reported at $33,447. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Radha Bernander Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,756 $156 $41–$563 $132
2022 $2,935 $185 $55–$649 $149
2023 $3,877 $199 $58–$717 $160
2024 $30,621 $206 $62–$740 $164
2025 $33,447 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Insulet Corporation $57,440 109 payments
  2. AstraZeneca Pharmaceuticals LP $2,117 73 payments
  3. Mannkind Corporation $1,846 74 payments
  4. Lilly USA, LLC $1,676 88 payments
  5. Dexcom, Inc. $1,368 81 payments
  6. Novo Nordisk Inc $1,318 78 payments
  7. Corcept Therapeutics $768 38 payments
  8. Abbott Laboratories $620 34 payments
  9. Intuity Medical Inc $590 28 payments
  10. AbbVie, Inc. $435 29 payments
  11. Other $5,459 242 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $56,490 65 payments
  2. Food and Beverage $16,805 796 payments
  3. Travel and Lodging $311 10 payments
  4. Education $30 3 payments
Products named General payments · program years 2021–2025
  1. Omnipod $57,440 109 payments
  2. FARXIGA $1,988 64 payments
  3. AFREZZA $1,846 74 payments
  4. Dexcom G6 Transmitter $1,081 72 payments
  5. Ozempic $1,024 62 payments
  6. RYBELSUS $841 51 payments
  7. MOUNJARO $775 40 payments
  8. Korlym $768 38 payments
  9. JARDIANCE $621 31 payments
  10. Pogo Automatic Blood Glucose Monitoring System $590 28 payments
  11. Other $9,440 457 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 45 drugs

Part D claims

1,770

Median for Physician Assistant: 241

Drug cost

$806,999

Median for Physician Assistant: $4,110

Branded share of claims

59%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 129 $186,122
Mounjaro Tirzepatide Brand 86 $106,537
Trulicity Dulaglutide Brand 58 $102,590
Jardiance Empagliflozin Brand 63 $61,588
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 40 $45,972
Farxiga Dapagliflozin Propanediol Brand 29 $33,541
Tradjenta Linagliptin Brand 39 $32,291
Tresiba Flextouch U-200 Insulin Degludec Brand 37 $31,693
Tresiba Flextouch U-100 Insulin Degludec Brand 56 $31,165
Humulin R U-500 Kwikpen Insulin Regular, Human Brand 16 $22,918

The 10 drugs with the highest cost, of 45 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$34,858

Medicare's payments for the services billed

Medicare patients

159

Average age 72

Services billed

1,091

105 women, 54 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 74%
Arthritis 51%
Ischemic heart disease 36%
Chronic kidney disease 36%
Depression 28%
Osteoporosis 23%
Heart failure 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Korlym
$458 — —
FARXIGA
$235 29 —
JARDIANCE
$229 63 —
MOUNJARO
$168 86 —
AFREZZA
$144 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

874 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record